Long-awaited results from the KEYNOTE-671 and CheckMate 816 trials indicate that neoadjuvant use of immune checkpoint inhibitors can extend event-free and overall survival in patients with non–small cell lung cancer.

©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.